1.Intestinal barrier in chronic gut and liver diseases: Pathogenesis and therapeutic targets.
Yongxin ZHANG ; Yameng LIU ; Xinyu LIANG ; Yingquan WEN ; Jingjie ZHAO ; Yong HE ; Qing XIE ; Cen XIE
Acta Pharmaceutica Sinica B 2025;15(11):5515-5536
The intestinal barrier is the primary defense that separates the host from the external environment, possessing several crucial physiological functions, including nutrient digestion, absorption, and protection against potentially harmful dietary antigens and pathogenic microorganisms. Nevertheless, various factors, such as diet, medications, circadian rhythm disturbances, gut microbiota, microbial metabolites, and genetic predisposition, can disrupt the intestinal barrier. Such disruption may lead to bacterial translocation, subsequently triggering enterohepatic and systemic inflammation. Impaired intestinal barrier has been implicated in the pathogenesis of numerous diseases, particularly chronic gut and liver diseases. In this review, we will summarize the fundamental functions of intestinal barrier and discuss clinical correlations between intestinal barrier dysfunction and diseases such as colitis, colorectal cancer, and chronic liver diseases including metabolic dysfunction-associated steatohepatitis, alcohol-associated liver disease, and primary sclerosing cholangitis. Additionally, we will also highlight some potential therapeutic strategies aimed at restoring barrier integrity to improve disease management.
2.Key recommendations in guidelines for the prevention,diagnosis,care and treatment for people with chronic hepatitis B infection released by the World Health Organization in 2024
Xiaowei AI ; Mengyang ZHANG ; Yameng SUN ; Hong YOU
Journal of Clinical Hepatology 2024;40(5):928-933
In March 2024,the World Health Organization released the latest version of guidelines for the prevention,diagnosis,care and treatment for people with chronic hepatitis B infection.The guidelines were updated in several aspects,including expanding and simplifying the indications for chronic hepatitis B treatment,adding alternative antiviral treatment regimens,broadening the indications for antiviral therapy to prevent mother-to-child transmission,improving the diagnosis of hepatitis B virus,and adding hepatitis D virus(HDV)testing.This article summarizes and gives an excerpt of the recommendations in the guidelines.
3.A new concept from a global perspective for expanding the treatment of chronic hepatitis B
Xiaowei AI ; Mengyang ZHANG ; Yameng SUN ; Hong YOU
Chinese Journal of Hepatology 2024;32(5):385-388
The global chronic hepatitis B (CHB) guidelines have gradually expanded treatment indications in order to accelerate the elimination and improve the treatment rate of hepatitis B virus (HBV) infection. This article analyzes the new treatment concepts for chronic hepatitis B at home and abroad from two aspects: expanding treatment by paying more attention to the long-term prognosis of the disease and maximizing the use of existing drugs in order to achieve the early goal of the World Health Organization's of eliminating viral hepatitis by 2030.
4.Define of Optimal Addition Period of Osteogenic Peptide to Accelerate the Osteogenic Differentiation of Human Pluripotent Stem Cells
Yameng SONG ; Hongjiao LI ; Zixuan WANG ; Jiamin SHI ; Jing LI ; Lu WANG ; Lingzi LIAO ; Shengqin MA ; Yun ZHANG ; Bin LIU ; Yaling YANG ; Ping ZHOU
Tissue Engineering and Regenerative Medicine 2024;21(2):291-308
BACKGROUND:
The addition of growth factiors is commonly applied to improve the osteogenic differentiation of stem cells. However, for human pluripotent stem cells (hPSCs), their complex differentiation processes result in the unknown effect at different stages. In this study, we focused on the widely used bone forming peptide-1 (BFP-1) and investigated the effect and mechanisms of its addition on the osteogenic induction of hPSCs as a function of the supplementation period.
METHODS:
Monolayer-cultured hPSCs were cultured in osteogenic induction medium for 28 days, and the effect of BFP-1 peptide addition at varying weeks was examined. After differentiation for varying days (0, 7, 14, 21 and 28), the differentiation efficiency was determined by RT–PCR, flow cytometry, immunofluorescence, and alizarin red staining assays. Moreover, the expression of marker genes related to germ layers and epithelial-mesenchymal transition (EMT) was investigated at day 7.
RESULTS:
Peptide treatment during the first week promoted the generation of mesoderm cells and mesenchymal-like cells from hiPSCs. Then, the upregulated expression of osteogenesis marker genes/proteins was detected in both hESCs and hiPSCs during subsequent inductions with BFP-1 peptide treatment. Fortunately, further experimental design confirmed that treating the BFP-1 peptide during 7–21 days showed even better performance for hESCs but was ineffective for hiPSCs.
CONCLUSION
The differentiation efficiency of cells could be improved by determining the optimal treatment period.Our study has great value in maximizing the differentiation of hPSCs by adding osteogenesis peptides based on the revealed mechanisms and promoting the application of hPSCs in bone tissue regeneration.
5.Evolution in the indications for anti-viral therapy in chronic hepatitis B
Jinjin LIU ; Mengyang ZHANG ; Yameng SUN ; Hong YOU
Journal of Clinical Hepatology 2023;39(6):1299-1303
In order to reduce the disease burden of chronic hepatitis B (CHB) and improve the treatment rate of CHB, the indications for anti-viral therapy have been gradually expanded and simplified in guidelines for the prevention and treatment of CHB released by Chinese Medical Association from 2005 to 2022. This article elaborates on the evolution in the indications for anti-viral therapy in CHB from the five aspects of converging indications of HBeAg-positive and HBeAg-negative CHB, reduction in the treatment threshold of HBV DNA, reduction in the treatment threshold of serum alanine aminotransferase, emphasis on the risk factors for disease progression, and gradual loosening of the requirements for virological indicators in patients with liver cirrhosis.
6.Paeoniflorin ameliorates diabetic cognitive dysfunction by inhibiting TLR4/NF-κB signaling in ovariectomized mice
Yameng ZHANG ; Haixia ZHOU ; Hui FANG ; Xinyu NAN ; Xiaoyu XU ; Gefei LI ; Ying YANG
Chinese Journal of Endocrinology and Metabolism 2023;39(2):141-148
Objective:To investigate the effect of paeoniflorin on toll-like receptor 4(TLR4)/nuclear transcription factor(NF-κB) signaling pathway of streptozotocin combined with ovariectomized mice, and to explore whether it can improve the cognitive impairment of ovariectomized diabetic mice.Methods:Ninety female C57BL/6J mice were divided into SHAM group, ovariectomy group, diabetes group(intraperitoneal injection of STZ 50 mg·kg -1·d -1 for 5 consecutive days), dual model group(DM modeling and OVX operation), paeoniflorin low-dose intervention group(OVX+ STZ+ L-PF 50 mg·kg -1·d -1), paeoniflorin high-dose intervention group(OVX+ STZ+ H-PF 100 mg·kg -1·d -1; all groups n=15). After 8 weeks of paeoniflorin intervention, their cognitive function was tested by behavioral experiments(Morris water maze and Y maze). The pathological changes of hippocampal tissue were observed by HE and Nissl staining. The mRNA expressions of TLR4, tumor necrosis factor-α(TNF-α), interleukin-1β(IL-1β) and interleukin-6(IL-6) in hippocampal tissues were detected by real-time fluorescence quantitative PCR. The expression of TLR4, NF-κB P65, TNF-α, IL-6, IL-1β, β-amyloid protein(Aβ), tau proteins, and p-tau proteins were detected by Western blot. Results:Compared with SHAM group, the learning and memory ability of ovariectomy group, diabetes group and dual model group decreased, hippocampal cells were damaged, and the expression of related gene mRNA and protein were increased, especially in dual model group; Compared with dual model group, paeoniflorin intervention could delayed the learning and memory impairment, improve cognitive function, reduce the degree of hippocampal injury, and decrease the expression levels of related gene mRNA and protein, The above changes were the most pronounced at paeoniflorin high-dose intervention group.Conclusion:Paeoniflorin improves cognitive dysfunction in ovariectomized diabetic mice by inhibiting TLR4/NF-κB signaling pathway.
7.Retrospection and reflection on standardized residency training system from the perspective of medical education history
Lifeng WEI ; Gangyu ZHANG ; Haonan JIA ; Yameng WANG ; Shuang ZHOU ; Ying WANG ; Yuanheng LI ; Zhuowa SHA ; Mingli JIAO
Chinese Journal of Medical Education Research 2023;22(2):236-240
Based on the national policies, regulations and documents on residency training, this paper sorts out the historical evolution of the standardized residency training system in China, and divides its development into four stages: preliminary exploration, local pilot, national trials, and implementation. It also puts forward some practical thoughts on its development law and future trend, such aspects as that the system reform follows the top-down administrative order and indicative plan, the system pays attention to the gradual implementation on the basis of summing up practical experience, and the system needs continuous implementation and improvement from the overall perspective.
8.Different treatment strategies in patients with HBeAg-positive and negative chronic hepatitis B
Mengyang ZHANG ; Shuyan CHEN ; Yameng SUN ; Hong YOU
Chinese Journal of Hepatology 2023;31(3):238-241
Patients with HBeAg-positive and negative chronic hepatitis B (CHB) have different immunological states and disease progression. Hence, the previously recommended antiviral therapy strategies for the two are different. In recent years, the antiviral indications have gradually eased, and the treatment goal has began to pursue clinical cure, as experts and scholars have gradually attached importance to the potential risk of disease progression in hepatitis B patients. Antiviral treatment strategies are gradually becoming uniform for patients with HBeAg-positive and negative. However, among them, HBeAg-negative patients can be combined with HBsAg quantification and other indicators to further screen the clinically cured dominant population in order to formulate the next treatment strategy.
9.Specific Regulation of m6A by SRSF7 Promotes the Progression of Glioblastoma.
Yixian CUN ; Sanqi AN ; Haiqing ZHENG ; Jing LAN ; Wenfang CHEN ; Wanjun LUO ; Chengguo YAO ; Xincheng LI ; Xiang HUANG ; Xiang SUN ; Zehong WU ; Yameng HU ; Ziwen LI ; Shuxia ZHANG ; Geyan WU ; Meisongzhu YANG ; Miaoling TANG ; Ruyuan YU ; Xinyi LIAO ; Guicheng GAO ; Wei ZHAO ; Jinkai WANG ; Jun LI
Genomics, Proteomics & Bioinformatics 2023;21(4):707-728
Serine/arginine-rich splicing factor 7 (SRSF7), a known splicing factor, has been revealed to play oncogenic roles in multiple cancers. However, the mechanisms underlying its oncogenic roles have not been well addressed. Here, based on N6-methyladenosine (m6A) co-methylation network analysis across diverse cell lines, we find that the gene expression of SRSF7 is positively correlated with glioblastoma (GBM) cell-specific m6A methylation. We then indicate that SRSF7 is a novel m6A regulator, which specifically facilitates the m6A methylation near its binding sites on the mRNAs involved in cell proliferation and migration, through recruiting the methyltransferase complex. Moreover, SRSF7 promotes the proliferation and migration of GBM cells largely dependent on the presence of the m6A methyltransferase. The two m6A sites on the mRNA for PDZ-binding kinase (PBK) are regulated by SRSF7 and partially mediate the effects of SRSF7 in GBM cells through recognition by insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2). Together, our discovery reveals a novel role of SRSF7 in regulating m6A and validates the presence and functional importance of temporal- and spatial-specific regulation of m6A mediated by RNA-binding proteins (RBPs).
Humans
;
Cell Line, Tumor
;
Cell Proliferation
;
Gene Expression Regulation, Neoplastic
;
Glioblastoma/genetics*
;
Methyltransferases/metabolism*
;
RNA Splicing Factors/metabolism*
;
RNA, Messenger/genetics*
;
RNA-Binding Proteins/metabolism*
;
Serine-Arginine Splicing Factors/metabolism*
;
RNA Methylation/genetics*
10.Application of measurable surgical guides in immediate implant placement and immediate restoration.
Yingkai WANG ; Chenyang XIE ; Yuqiang ZHANG ; Yameng ZHANG ; Tinglu FANG ; Haiyang YU
West China Journal of Stomatology 2022;40(6):731-739
This article reports a case of using immediate implant placement and immediate restoration combined with measurable implant surgical guides to restore compromised maxillary incisors caused by dental trauma. Target restoration was designed in the exoCAD software preoperatively, intraoral measurements were obtained in three directions, and the correct position of virtual implants was determined in BlueSky Plan 4. Afterward, measurable implant guides were designed and fabricated by 3D printing. Under the guidance of the measurable implant surgical guides and intraoperative measurement, the entry point was determined, the axial direction was verified when drilling to half the depth, and the 3D position was verified when drilling to total depth. Implants were inserted followed by verification once again. The temporary restoration, which was designed based on the target restoration and emergence profile of the original teeth and milled preoperatively, was connected to the implant immediately after surgery. Postoperative accuracy analysis showed that the mean linear deviations between the actual implant position and the pre-planned position were (0.57±0.17) mm at the entry point and (0.82±0.27) mm at the apex, and the mean angular deviation was (1.86±0.89) °, demonstrating that precise implant placement and immediate restoration were implemented.
Humans
;
Dental Implantation, Endosseous
;
Dental Implants
;
Surgery, Computer-Assisted
;
Imaging, Three-Dimensional
;
Software

Result Analysis
Print
Save
E-mail